Levetiracetam but not valproate inhibits function of CD8+ T lymphocytes

Seizure

Volumn 22, Issue 6, 2013, Pages 462-466

  Li, Gang ^a,b,c   Nowak, Mareike ^a,d   Bauer, Sebastian ^a   Schlegel, Kerstin ^a   Stei, Susanne ^a   Allenhöfer, Lena ^d   Waschbisch, Anne ^d   Tackenberg, Björn ^a   Höllerhage, Matthias ^a   Höglinger, Günter U ^a   Wegner, Sven ^a   Wang, Xin ^c   Oertel, Wolfgang H ^a   Rosenow, Felix ^a   Hamer, Hajo M ^a,d  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b TONGJI UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Apoptosis; CD8+ T lymphocytes; Levetiracetam; Perforin; SV2A; Valproate

Indexed keywords

CELL PROTEIN; ETIRACETAM; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; PERFORIN; SYNAPTIC VESICLE PROTEIN 2A; UNCLASSIFIED DRUG; VALPROIC ACID; VIRUS PROTEIN;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOTOXICITY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADOLESCENT; ADULT; ANTICONVULSANTS; ANTIGENS, CD; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PERFORIN; PIRACETAM; STATISTICS, NONPARAMETRIC; VALPROIC ACID; YOUNG ADULT;

EID: 84878884658     PISSN: 10591311     EISSN: 15322688     Source Type: Journal    
DOI: 10.1016/j.seizure.2013.03.006     Document Type: Article

References (38)

1. F. Vigevano Levetiracetam in pediatrics Journal of Child Neurology 20 2005 87 93
2. T. De Smedt, R. Raedt, K. Vonck, and P. Boon Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug CNS Drug Reviews 13 2007 57 78
3. B.A. Lynch, N. Lambeng, K. Nocka, P. Kensel-Hammes, S.M. Bajjalieh, and A. Matagne The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam Proceedings of the National Academy of Sciences of the United States of America 101 2004 9861 9866
4. E. Ben-Menachem, and U. Falter Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy Epilepsia 41 2000 1276 1283
5. J.J. Cereghino, V. Biton, B. Abou-Khalil, F. Dreifuss, L.J. Gauer, and I. Leppik Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial Neurology 55 2000 236 242
6. T. Betts, T. Waegemans, and P. Crawford A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy Seizure 9 2000 80 87
7. S.D. Shorvon, A. Löwenthal, D. Janz, E. Bielen, and P. Loiseau Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures Epilepsia 41 2000 1179 1186
8. J. French, P. Edrich, and J.A. Cramer A systematic review of the safety profile of levetiracetam: a new antiepileptic drug Epilepsy Research 47 2001 1 2
9. C.L. Harden Safety profile of levetiracetam Epilepsia 42 2001 36 49
10. M. Nowak, S. Bauer, A. Haag, S. Cepok, A. Todorova-Rudolph, and B. Tackenberg Interictal alterations of cytokines and leukocytes in patients with active epilepsy Brain, Behavior, and Immunity 25 2011 423 428
11. + T cell effector activity is dictated by cognate peptide concentration Journal of Immunology 172 2004 6407 6417
12. + lymphocytes can control HIV infection in vitro by suppressing virus replication Science 234 1986 1563 1566
13. B.D. Walker, S. Chakrabarti, B. Moss, T.J. Paradis, T. Flynn, and A.G. Durno HIV-specific cytotoxic T lymphocytes in seropositive individuals Nature 328 1987 345 348
14. R.A. Van Lier, I.J. ten Berge, and L.E. Gamadia Human CD8(+) T-cell differentiation in response to viruses Nature Reviews Immunology 3 2003 931 939
15. + T cell differentiation during viral infection Immunity 27 2007 393 405
16. A.G. Marson, A.M. Al-Kharusi, M. Alwaidh, R. Appleton, G.A. Baker, and D.W. Chadwick The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial Lancet 369 2007 1016 1026
17. R. Kawagoe, H. Kawagoe, and K. Sano Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways Leukemia Research 26 2002 495 502
18. A. Kuendgen, M. Schmid, R. Schlenk, S. Knipp, B. Hildebrandt, and C. Steidl The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia Cancer 106 2006 112 119
19. I. Bokelmann, and U. Mahlknecht Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins Molecular Medicine 14 2008 20 27
20. Y. Araki, M. Fann, R. Wersto, and N.P. Wenig Histone acetylation facilitates rapid and robust memory CD8 T cell response through differential expression of effector molecules (eomesodermin and its targets: perforin and granzyme B) Journal of Immunology 180 2008 8102 8108
21. S. Bauer, M. Köller, S. Cepok, A. Todorova-Rudolph, M. Nowak, and W.A. Nockher NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy Experimental Neurology 211 2008 370 377
22. S. Bauer, S. Cepok, A. Todorova-Rudolph, M. Nowak, M. Köller, and R. Lorenz Etiology and site of temporal lobe epilepsy influence postictal cytokine release Epilepsy Research 86 2009 82 88
23. P.N. Patsalos, D.J. Berry, B.F.D. Bourgeois, J.C. Cloyd, T.A. Glauser, and S.I. Johannessen Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies Epilepsia 49 2008 1239 1276
24. A. Weren, B. Bonnekoh, B. Schraven, H. Gollnick, and A. Ambach A novel flow cytometric assay focusing on perforin release mechanisms of cytotoxic T lymphocytes Journal of Immunological Methods 289 2004 17 26
25. + T cells by a flow cytometric assay for degranulation Journal of Immunological Methods 281 2003 65 78
26. M. Fukuda Lysosomal membrane glycoproteins. Structure, biosynthesis, and intracellular trafficking Journal of Biological Chemistry 266 1991 21327 21330
27. G.L. Suidan, J.W. Dickerson, Y. Chen, J.R. McDole, P. Tripathi, and I. Pirko CD8 T cell-initiated vascular endothelial growth factor expression promotes central nervous system vascular permeability under neuroinflammatory conditions Journal of Immunology 184 2010 1031 1040
28. N. Marchi, A.J. Johnson, V. Puvenna, H.L. Johnson, W. Tierney, and C. Ghosh Modulation of peripheral cytotoxic cells and ictogenesis in a model of seizures Epilepsia 52 2011 1627 1634
29. E.A. Van Vliet, S. da Costa Araújo, S. Redeker, R. van Schaik, E. Aronica, and J.A. Gorter Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy Brain 130 2007 521 534
30. N. Marchi, L. Angelov, T. Masaryk, V. Fazio, T. Granata, and N. Hernandez Seizure-promoting effect of blood-brain barrier disruption Epilepsia 48 2007 732 742
31. P.F. Fabene, G. Navarro Mora, and M. Martinello A role for leukocyte-endothelial adhesion mechanisms in epilepsy Nature Medicine 14 2008 1377 1383
32. J.K. Kleen, and G.L. Holmes Brain inflammation initiates seizures Nature Medicine 14 2008 1309 1310
33. A. Schietinger, J.J. Delrow, R.S. Basom, J.N. Blattman, and P.D. Greenberg Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state Science 10 2012 723 727
34. K. Buckley, and R.B. Kelly Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells Journal of Cell Biology 100 1985 1284 1294
35. S.M. Bajjalieh, K. Peterson, M. Linial, and R.H. Scheller Brain contains two forms of synaptic vesicle protein 2 Proceedings of the National Academy of Sciences of the United States of America 90 1993 2150 2154
36. S.M. Bajjalieh, G.D. Frantz, J.M. Weimann, S.K. McConnell, and R.H. Scheller Differential expression of synaptic vesicle protein 2 (SV2) isoform Journal of Neuroscience 14 1994 5223 5235
37. T. Xu, and S.M. Bajjalieh SV2 modulates the size of the readily releasable pool of secretory vesicles Nature Cell Biology 3 2001 691 698
38. K.M. Crowder, J.M. Gunther, T.A. Jones, B.D. Hale, H.Z. Zhang, and M.R. Peterson Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A) Proceedings of the National Academy of Sciences of the United States of America 96 1999 15268 15273